Loading clinical trials...
Loading clinical trials...
A Phase I Study of INCB024360 (Epacadostat) Alone, INCB024360 in Combination With Pembrolizumab (MK-3475), and INCB024360 and Pembrolizumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors (KEYNOTE-434)
Conditions
Interventions
Epacadostat 25 mg
Epacadostat 100 mg
+6 more
Start Date
August 23, 2016
Primary Completion Date
November 20, 2020
Completion Date
November 20, 2020
Last Updated
August 19, 2022
NCT00026884
NCT07213804
NCT07169851
NCT07159659
NCT06662786
NCT07191730
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions